» Articles » PMID: 20017197

Intrathecal Immune Responses to EBV in Early MS

Overview
Journal Eur J Immunol
Date 2009 Dec 18
PMID 20017197
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

EBV has been consistently associated with MS, but its signature in the CNS has rarely been examined. In this study, we assessed EBV-specific humoral and cellular immune responses in the cerebrospinal fluid (CSF) of patients with early MS, other inflammatory neurological diseases (OIND) and non-inflammatory neurological diseases (NIND). The neurotropic herpesvirus CMV served as a control. Virus-specific humoral immune responses were assessed in 123 consecutive patients and the intrathecal recruitment of virus-specific antibodies was expressed as antibody indexes. Cellular immune responses tested in the blood of 55/123 patients were positive in 46/55. The CD8(+) CTL responses of these 46 patients were assessed in the blood and CSF using a CFSE-based CTL assay. We found that viral capsid antigen and EBV-encoded nuclear antigen-1, but not CMV IgG antibody indexes, were increased in early MS as compared with OIND and NIND patients. There was also intrathecal enrichment in EBV-, but not CMV-specific, CD8(+) CTL in early MS patients. By contrast, OIND and NIND patients did not recruit EBV- nor CMV-specific CD8(+) CTL in the CSF. Our data, showing a high EBV-, but not CMV-specific intrathecal immune response, strengthen the association between EBV and MS, in particular at the onset of the disease.

Citing Articles

Ocrelizumab Alters Cytotoxic Lymphocyte Function While Reducing EBV-Specific CD8 T-Cell Proliferation in Patients With Multiple Sclerosis.

Abbadessa G, Lepore M, Bruzzaniti S, Piemonte E, Miele G, Signoriello E Neurol Neuroimmunol Neuroinflamm. 2024; 11(4):e200250.

PMID: 38662990 PMC: 11087045. DOI: 10.1212/NXI.0000000000200250.


Disease-Modifying Treatments for Multiple Sclerosis Affect Measures of Cellular Immune Responses to EBNA-1 Peptides.

Dungan L, Dunne J, Savio M, Kalaszi M, McElheron M, Lynagh Y Neurol Neuroimmunol Neuroinflamm. 2024; 11(3):e200217.

PMID: 38547427 PMC: 11073890. DOI: 10.1212/NXI.0000000000200217.


Risk factors for multiple sclerosis in the context of Epstein-Barr virus infection.

Hedstrom A Front Immunol. 2023; 14:1212676.

PMID: 37554326 PMC: 10406387. DOI: 10.3389/fimmu.2023.1212676.


Epstein-Barr virus and multiple sclerosis: moving from questions of association to questions of mechanism.

Thomas O, Rickinson A, Palendira U Clin Transl Immunology. 2023; 12(5):e1451.

PMID: 37206956 PMC: 10191779. DOI: 10.1002/cti2.1451.


The CD8 T Cell-Epstein-Barr Virus-B Cell Trialogue: A Central Issue in Multiple Sclerosis Pathogenesis.

Veroni C, Aloisi F Front Immunol. 2021; 12:665718.

PMID: 34305896 PMC: 8292956. DOI: 10.3389/fimmu.2021.665718.